ACU-193 (Acumen Pharmaceuticals)

N/A

Report date: 2025/06/11 11:07:38

Base Information

Drug NameACU-193 (Acumen Pharmaceuticals)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Protein drugs > Enzyme > Recombinant enzymeBiologics > Protein drugs > Recombinant protein > Recombinant enzyme
Mechanisms of ActionBeta amyloid A4 protein aggregation inhibitorsBeta amyloid A4 protein inhibitorsNeuroprotectants
TargetsBeta amyloid A4 protein
Therapy Area/IndicationsAlzheimer Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAcumen Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesHalozyme Therapeutics IncAcumen Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsAlzheimer Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A